Applications of HUB Tumor Organoids in Oncology Drug Discovery
Presenter: Dr Rajendra Kumari,
Global Head of Scientific Communications
Tumor organoids offer an innovative and predictive in vitro platform to revolutionize oncology drug development. Derived from cancer stem cells, organoids provide a unique 3D in vitro system recapitulating the histo- and molecular pathology of their corresponding in vivo tumor.
Organoids are generated following protocols established by Hubrecht Organoid Technology (HUB) from both patient tumors as well as PDX models, offering the flexibility to rapidly establish large libraries of PDX-derived organoids with paired in vivo models. These libraries present multiple drug development opportunities, including large scale single agent and combination regimen screening.
In this webinar Dr Rajendra Kumari details many applications of tumor organoids in oncology drug discovery. She also explores how to use matched organoid/PDX models in a unique and predictive paired in vitro/in vivo platform to improve translation of preclinical data into clinical success.
Watch this Webinar to Learn:
- How to apply tumor organoids to large scale drug screening, in vivo model selection, and in silico drug discovery
- How to successfully predict patient response using organoids
- How organoids represent a superior and innovative in vitro system to disrupt traditional oncology drug discovery
- The “biological equivalence” between patient-derived and PDX-derived organoids
- How to accelerate drug development using our unique matched in vitro PDX-derived organoid (PDXO)/in vivo PDX pairs for improved predictivity
Who Should Watch:
- Decision makers from biotech and pharmaceutical companies who want to understand how to enhance oncology drug discovery programs through organoid applications
- Drug developers who are looking for relevant in vitro models with matched in vivo models for optimal predictivity
- Scientists interested in using in vitro models that recapitulate a human organ’s function in vivo
About The Presenter:
Dr Rajendra Kumari is the Global Head of Scientific Communications for Crown Bioscience, providing scientific guidance and communications on company products, services, and R&D.
Rajendra received her PhD from the University of Leicester in Molecular Pharmacology, following which she joined the lab of Prof. Sue Watson as a postdoctoral fellow in the Division of Pre-clinical Oncology, School of Clinical Sciences, University of Nottingham (UoN). In 2005, Rajendra took the role of Project and Business Manager of the Preclinical Oncology Services (PRECOS) contract research business unit where she built up and managed the portfolio of preclinical in vitro and in vivo projects, products, team and clients, as well as marketing and developing the commercial processes of PRECOS.
Rajendra’s expertise in cancer cell biology and model development helped to build PRECOS, develop an academic career as a lecturer in the School of Clinical Sciences, as well as co-founding the Ex Vivo Pharmacology Centre of Excellence (UoN), which recapitulates the tumor microenvironment through use of clinically-derived tissue. Rajendra was pivotal in the growth of the business unit and commercialization of research which led to the establishment of the spinout of PRECOS Ltd in 2010, acting as Chief Operations Officer, Board Director and co-founder, until merger with CrownBio in July 2013 where she then acted as GM/CSO for CrownBio UK for 4 years.
Rajendra is a member of the American Association of Cancer Research, British Association of Cancer Research, the NC3Rs Cancer Research Advisory Group, and has authored over 40 abstracts and publications.